Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 LOXO-435 study in advanced or metastatic solid tumors with FGFR3 alterations
NL-OMON59881Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vepugratinib in Nonhematologic neoplasms, sponsored by Eli Lilly and Company. Started Mar 2024; status: recruiting.
02
Drugs
vepugratinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59881.